NCT05310448

Tumor Treating Fields for the Treatment of Brainstem Gliomas

Tumor Treating Fields: Pilot Study of Adjuvant Treatment for Brainstem Gliomas

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Emory University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields called tumor treating fields (TTFields), which interfere with cancer cell division. TTFields may prevent growth or decrease size of gliomas in patients

Detailed description

PRIMARY OBJECTIVE: I. To evaluate the safety and tolerability of tumor treating fields in combination with standard of care radiotherapy and chemotherapy in patients with brainstem gliomas. SECONDARY OBJECTIVE: I. To evaluate the anti-tumor activity of the combination of radiotherapy, chemotherapy, and tumor treating fields by assessing progression-free survival (PFS), overall response rate, and overall survival (OS). TERTIARY/EXPLORATORY OBJECTIVE: I. To assess the effects of the tumor treating fields on neurocognitive function. OUTLINE: Beginning after start of standard of care radiation therapy, patients wear the Optune device for at least 18 hours per day for 12 months in the absence of disease progression or unacceptable toxicity. During study treatment, patients are followed up at 3, 6, 9, and 12 months. After study treatment, patients are followed up every 3-6 months.

Conditions

• Glioma

Interventions

Type	Name	Description
DEVICE	Optune device	Wear Optune device

Timeline

• Start date: 2022-05-11
• Primary completion: 2026-09-01
• Completion: 2027-05-01
• First posted: 2022-04-05
• Last updated: 2025-09-26

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated device study